Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: In this role you will join the Cancer Genomics group within Clinical Biomarker Development, which sits in the Translational Medicine department to develop biomarker, technology, and computational strategies for our RAS(ON) inhibitor programs. You will drive the application of advanced genomics analyses & emerging NGS technologies to maximize insight generation from clinical samples in our Phase I-III studies. This role offers the chance to work in a collaborative and innovative environment, including on cross-functional teams with other computational scientists, biomarker leads, biostatisticians, and preclinical scientists.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Entry Level
Education Level
Ph.D. or professional degree